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Summary
Estradiol regulates serotonin 1A(5-HT1A) receptor signaling. Since desensitization of 5-HT1A
receptors may be an underlying mechanism by which selective serotonin reuptake inhibitors
(SSRIs) mediate their therapeutic effects and combining estradiol with SSRIs enhances the
efficacy of the SSRIs, it is important to determine which estrogen receptors are capable of
desensitizating 5-HT1A receptor function. We previously demonstrated that selective activation of
the estrogen receptor, GPR30, desensitizes 5-HT1A receptor signaling in rat hypothalamic
paraventricular nucleus(PVN). However, since estrogen receptor beta(ERβ), is highly expressed in
the PVN, we investigated the role of ERβ in estradiol-induced desensitization of 5-HT1A receptor
signaling. We first showed that a selective ERβ agonist, diarylpropionitrile(DPN) has a 100-fold
lower binding affinity than estradiol for GPR30. Administration of DPN did not desensitize 5-
HT1A receptor signaling in rat PVN as demonstrated by agonist-stimulated hormone release.
Second, we used a recombinant adenovirus containing ERβ siRNAs to decrease ERβ expression in
the PVN. Reductions in ERβ did not alter the estradiol-induced desensitization of 5-HT1A receptor
signaling in oxytocin cells. In contrast, in animals with reduced ERβ, estradiol administration,
instead of producing desensitization, augmented the ACTH response to a 5-HT1A agonist.
Combined with the results from the DPN treatment experiments, desensitization of 5-HT1A
receptor signaling does not appear to be mediated by ERβ in oxytocin cells, but that ERβ, together
with GPR30, may play a complex role in central regulation of 5-HT1A-mediated ACTH release.
Determining the mechanisms by which estrogens induce desensitization may aid in the
development of better treatments for mood disorders.
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Introduction
Women past the age of 40 begin to experience fluctuation, then a decline in the levels of
estrogens resulting in a peri- to post-menopausal state (Banger, 2002). Decreased levels of
estrogens are associated with various neuropsychiatric disorders such as depression, anxiety,
and panic disorders in women (Arpels, 1996). One particular hallmark of these disorders is a
change in serotonergic function (Halbreich, 1990; Jimerson et al., 1997; Joffe and Cohen,
1998; Menkes et al., 1994; Ressler and Nemeroff, 2000), and particularly in serotonin 1A
(5-HT1A) receptor function (Lemonde et al., 2003; Savitz et al., 2009; Shively and Bethea,
2004).
Several groups have shown that estrogen treatment modulates 5-HT1A receptor signaling.
There is evidence for both species and regional differences in the regulation of 5-HT1A
receptors following estrogen treatment. In rat studies, either a single injection or two-three
days of estrogen treatment results in a decrease in 5-HT1A receptor gene expression
(Osterlund and Hurd, 1998), G protein coupling (Mize and Alper, 2000), and 5-HT1A
receptor function (D'Souza et al., 2004; Jackson and Uphouse, 1996, 1998; Raap et al.,
2000) in the limbic region, cortex, and dorsal raphe nucleus. Similarly, chronic estrogen
treatment in nonhuman primates and rats resulted in a decrease in 5-HT1A receptor gene
expression (Birzniece et al., 2001), 5-HT1A receptor density, and 5-HT1A receptor-G protein
coupling in the dorsal raphe nucleus (Lu and Bethea, 2002; Pecins-Thompson and Bethea,
1999). Following chronic estrogen treatment, 5-HT1A receptor gene expression (Birzniece et
al., 2001) and 5-HT1A receptor-G protein coupling in cortical and hippocampal regions
decreased without changes in 5-HT1A receptor density in rats (Le Saux and Di Paolo, 2005).
In contrast, in nonhuman primates there was no evidence for changes in 5-HT1A receptor
gene expression (Gundlah et al., 1999) or 5-HT1A receptor-G protein coupling in the
hypothalamus (Lu and Bethea, 2002). The regional differences may be indicative of
different estrogen receptor subtypes involved in the regulation of 5-HT1A receptors.
Understanding which estrogen receptor is involved in the regulation of hypothalamic 5-
HT1A receptors may be important for improving the current therapies for mood disorders.
Clinical studies have demonstrated that combining estrogen with SSRIs enhances the
efficacy of the SSRIs in treating women with mood disorders and hot flushes (Schneider et
al., 1997), but the mechanism by which this occurs is not known. Desensitization of
somatodendritic 5-HT1A autoreceptors in the midbrain and postsynaptic 5-HT1A receptors in
the hypothalamus are considered to be a likely underlying mechanism by which
antidepressants, particularly SSRIs, mediate their therapeutic effects (Bosker et al., 2001;
Chaput et al., 1986; Czachura and Rasmussen, 2000; Kreiss and Lucki, 1995). In contrast to
SSRI administration which takes one-two weeks to produce a full desensitization (Li et al.,
1997; Li et al., 1996), beta-estradiol 3-benzoate (EB) treatment results in partial
desensitization of the 5-HT1A receptor signaling in the paraventricular nucleus of the
hypothalamus (PVN) within 2 days (D'Souza et al., 2004; Raap et al., 2000).
Activation of the post-synaptic 5-HT1A receptors in the PVN stimulates the release of the
hormones oxytocin, adrenocorticotropin hormone (ACTH), and corticosterone (Osei-Owusu
et al., 2005). Based on our previous study of co-localization of estrogen receptors with 5-
HT1A receptors, oxytocin and CRH, we know that 5-HT1A receptors co-localize with both
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oxytocin and CRH in the PVN (Xu et al., 2008). Oxytocin is a neurohormone with
anxiolytic and antidepressant activity and it is important in humans for socialization (Gimpl
and Fahrenholz, 2001) whereas ACTH and corticosterone are pituitary and adrenal
hormones respectively, associated with stress (Carrasco and Van de Kar, 2003). Measuring
these hormones following activation of 5-HT1A receptors provides an indication of
desensitization of 5-HT1A receptor activity in the PVN and can be used to assess the delay in
the desensitization response to EB and other drug treatments.
We recently found that the G protein coupled estrogen receptor, GPR30, is involved in the
desensitization of the 5-HT1A receptor signaling in the PVN (Xu et al., 2009). In addition to
GPR30, PVN neurons also express the nuclear estrogen receptors, estrogen receptor alpha
(ERα) and beta (ERβ). The density of ERβ is much higher than that of ERα in the PVN
(Laflamme et al., 1998), especially in oxytocin neurons (Alves et al., 1998; Hrabovszky et
al., 2004; Simonian and Herbison, 1997). Therefore in the current study, we focused on
whether ERβ is involved in the EB-induced desensitization of the 5-HT1A receptors in the
PVN. We used two complimentary approaches to address this question. In one experiment,
we asked whether a selective ERβ agonist, diarylpropionitrile (DPN) desensitizes 5-HT1A
receptors in the PVN. In a second complimentary experiment, we decreased the expression
of the ERβ by injecting a recombinant adenovirus containing a small interference RNA




Female Sprague-Dawley rats (225–275g) from Harlan (Indianapolis, IN) were housed two
per cage in a temperature-, humidity-, and light-controlled room (12h light/dark cycle, lights
on 0700 h). Food and water were available ad libitum. All procedures were conducted in
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory
Animals (NIH Publication 85-23, revised 1996) and as approved by the University of
Kansas Institutional Animal Care and Use Committee. All efforts were made to minimize
animal suffering and to reduce the number of animals used.
Drugs
EB was purchased from Sigma Research Biomedical Inc. (St. Louis, MO). DPN and (+)-8-
hydroxy-2-dipropylaminotetralin hydrobromide ((+)8-OH-DPAT) were purchased from
Tocris (Ellisville, MO). (+)8-OH-DPAT was dissolved in saline at a concentration of 0.2
mg/ml and administered at a dose of 0.2 mg/kg, sc. At this near maximal effective dose of
(+)8-OH-DPAT, the 5-HT1A receptor antagonist WAY-100635 blocks the hormone
response by (+)8-OH-DPAT suggesting that the effect is due to selective activation of 5-
HT1A receptors over 5-HT7 receptors at this dose (Critchley et al., 1994; Vicentic et al.,
1998). EB was first dissolved in 100% ethanol to a concentration of 1 mg/ml and then
diluted with sesame oil to a concentration of 5 µg/ml. The EB solution and sesame oil were
administrated at 0.4 ml/kg (EB dose 2 µg/kg, sc). DPN was first dissolved in 100% DMSO
to a concentration of 40 mg/ml, and then this solution was diluted to 2 mg/ml with 25%
DMSO/saline (administrated at 1 ml/kg, sc). The DPN dose was chosen based on previous
studies (Le Saux et al., 2006; Lund et al., 2005; Mazzucco et al., 2006). All of these
solutions were made fresh before injection.
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Experiment 1: Effect of the selective estrogen receptor beta (ERβ) agonist, DPN, on 5-HT1A
receptor function
DPN Binding to GPR30—DPN is a selective ERβ agonist with an approximately 100-
fold higher affinity for ERβ than estrogen receptor alpha (ERα) (Lund et al., 2005).
However, no data were available regarding the affinity of DPN for GPR30. Since GPR30
can mediate EB-induced desensitization of 5-HT1A receptors (Xu et al., 2009), it was
necessary to determine the relative affinity of DPN for GPR30. DPN binding to human
recombinant GPR30 was examined by a membrane estrogen radioreceptor assay described
previously (Thomas et al., 2005). Plasma membranes of human recombinant GPR30-
transfected HEK293 cells were prepared by homogenization with a glass homogenizer
followed by sequential centrifugation steps of 1000×g for 7 minutes and 20,000×g for 20
min (Pang et al., 2008). An aliquot (0.125mg protein in 250µl) of the resulting plasma
membrane pellet was incubated for 30 minutes with 2 nM of [3H]-estradiol-17β ([3H]-E2) in
the presence of E2 or DPN at the concentrations 10−10- 10−5 M. The bound [3H]E2 was
separated from free [3H]E2 using glass-fiber filters. Competition binding was expressed as a
percentage of maximum specific binding. The competitive binding assay was repeated three
times.
Effect of DPN treatment on 5-HT1A receptor function—Rats were ovariectomized
by removing both ovaries via a single ventral midline incision. Prior to surgery, an
intraperitoneal injection of a mixture of ketamine hydrochloride (100 mg/kg) plus xylazine
hydrochloride (10 mg/kg) was used to anesthetize the animals. Five days after surgery,
animals were given subcutaneous (sc) injections of either DPN (2 mg/kg) or 25% DMSO/
saline (vehicle) once a day for two days. A 5-HT1A receptor agonist, (+)8-OH-DPAT (0.2
mg/kg, sc) was injected 18 hours following the last injection of DPN or vehicle. Fifteen
minutes later, animals were sacrificed by decapitation. Trunk blood was collected in
centrifuge tubes containing 0.5 ml EDTA (0.3 M, pH 7.4). Plasma was stored at −80°C until
radioimmunoassays were conducted.
Experiment 2: Effect of recombinant adenovirus containing ERβ siRNA on EB-induced
desensitization of 5-HT1A receptors
Generation of recombinant adenoviruses containing ERβ siRNAs—To identify
the potential siRNAs for ERβ, four ERβ siRNAs were selected for initial testing from a list
of ERβ siRNAs suggested by a siRNA design program siDesign Center (Dharmacon, Inc.,




siRNA4:GUCAAAGGUUCCGUGAGUUAUU. ERβ siRNA duplexes (Dharmacon, Inc.,
Thermo Fisher Scientific, Lafayette, CO) were transfected into PC-12 cells. The levels of
ERβ mRNA in the cells were determined 48 hours later using RT-PCR.
Based on the extent of ERβ mRNA reduction, selected ERβ siRNAs were further evaluated
using a pSOS-HUS vector (provided by Dr. TC He at the University of Chicago). The
pSOS-HUS contains an siRNA site and a target gene site that allows transfection of siRNAs
and the target gene into the same cells. The target gene is fused with an enhanced green
fluorescent protein (GFP) gene, so that the expression of the target gene can be directly
observed by fluorescence microscopy. The rat ERβ coding region was amplified by PCR
with primers encoding 417–441 (Forward: ATGACATTCTACAGTCCTGCTGTG) and
1874-1851 (reverse: TCACTGAGACTGTAGGTTCTGGG) of ERβ cDNA sequence
(Accession # NM_012754). The PCR product was then inserted into the target site of pSOS-
HUS and fused with GFP (SOSERβ-HUS). After digestion with Sfi I at the siRNA insertion
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site of SOS-ERβ-HUS, a double-stranded DNA oligonucleotide encoding ERβ siRNA1 or 2
sequences was ligated into SOS-ERβ-HUS to generate SOS-ERβ-siRNA-HUS.
The SOS-ERβ-siRNA-HUSs or SOS-ERβ-HUS was then transfected into HEK 293 cells to
evaluate the knockdown efficiency of the ER-beta siRNAs. When comparing the SOS-ERβ-
siRNA-HUSs transfected cells with those transfected with SOS-ERβ-HUS, a reduction in
the number and density of GFP-containing cells indicates the efficiency of knockdown by
the siRNA. In a separate experiment, the SOS-ERβ-siRNA-HUSs or SOS-ERβ-HUS was
transfected into PC12 cells. 48 hours later, the cells were collected and lysed. The ERβ
levels in the cell lysis were examined by western blot.
The siRNAs in the SOS-ERβ-siRNA-HUS that reduced the percentage and brightness of
GFP-containing cells were selected and inserted into pSES-HUS vector (a shuttle vector for
adenovirus). The SES-ERβ-siRNA-HUSs were further recombined into Ad-Easy-1 vector to
generate high titer adenoviruses containing the siRNAs as described by Luo et al (He et al.,
1998; Luo et al., 2007) and our previous publication (Li et al., 2004). Red fluorescent
protein (RFP) is expressed independently along with the siRNAs by the adenoviral vector.
RFP can be used as a marker for viral infection. The high titer ERβ-siRNA1-Ad and ERβ-
siRNA2-Ad (~1010 infectious viral particles/ml) were stored at −80°C. To prevent tissue
damage induced by the high salt storage-solution, the high titer recombinant adenovirus
ERβ-siRNA-Ads (about 30 µl) were dialyzed with saline (about 1L) for at least 40 min at
4°C followed by 1:1 dilution with saline before use.
To evaluate ERβ-siRNA-Ads in vivo, the high titer ERβ-siRNA-Ads were unilaterally
injected into the PVN using stereotaxic technique at a rate of 0.2 µl/min (1 µl/side at the
coordinates of AP= −1.8, ML= 0.5 and DV= −8.3 mm with respect to bregma (Paxinos and
Watson, 2007). The needle was left at the site of injection for 20 minutes to reduce
movement of the viral solution into the needle track. 7 and 10 days after the injection, rats
were decapitated and the brains were collected to evaluate the efficiency of knockdown of
ERβ expression by the siRNAs. Regions with viral infection as indicated by RFP and the
contra-lateral regions (as controls) were punched for immunoblot analysis of ERβ.
Effect of ERβ-siRNA-Ads on EB-induced desensitization of 5-HT1A receptors
—After demonstrating that ERβ expression was decreased by the virus containing siRNAs
for ERβ, the next experiment was to test the effect of ERβ knockdown on 5-HT1A receptor
function. In this experiment, rats were anesthetized and ovariectomized as described above
in Experiment 1. On the same day as the ovariectomy, either a control adenovirus (Ad-track,
1µL/side) or ERβ siRNA-Ads (mixed ERβ-siRNA1-Ad and ERβ-siRNA2-Ad, 1µL/site) was
bilaterally microinjected into the PVN as described above. The control adenovirus (Ad-
track) was generated by recombination of an empty Ad-track shuttle vector with the
adenoviral vector.
On days 5 and day 6 after ovariectomy and viral injections, rats were injected with EB (2µg/
kg, 0.4ml/kg) or sesame oil subcutaneously once a day for 2 days. To assess 5-HT1A
receptor signaling in the PVN, the 5-HT1A receptor agonist, (+)8-OH-DPAT (0.2 mg/kg, sc)
was injected 18 hours after the last EB or oil injection. Animals were sacrificed 15 minutes
after the (+)8-OH-DPAT injection as described in Experiment 1. Trunk blood was collected
for hormone radioimmunoassays. The brains were removed and flash-frozen in isopentane
chilled over dry ice, and stored at −80°C until further analysis.
Coronal brain sections were cut in a cryostat microtome to obtain a 700 µm thick section at
the level of the PVN (Paxinos and Watson, 2007). The PVN was dissected for western blot
analysis of ERβ receptors. In addition, 16 µm thick sections, before and after the 700 µm
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PVN section, were collected and mounted on microscope slides. These sections were used to
determine whether the adenovirus was correctly microinjected into the PVN.
Immunoblot assay for ERβ receptors
The dissected brain tissues were homogenized in buffer (10 mM Tris, pH7.4, 100 mM NaCl,
1mM EDTA, 1 mM DTT, 0.1% sodium cholate and 1× protease inhibitor cocktail) by
sonication 5 sec × 3 time with 30 sec intervals in ice. After centrifugation at 25,000 × g,
4°C, the supernatant was used for western blots. The protein concentration was determined
using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Rockford, IL).
ERβ levels in cell lysates or brain homogenates were measured using immunoblot analysis.
The proteins (3 µg/lane) were resolved on a 12% SDS-page gel followed by transferred to a
PVDF membrane. The membranes were then incubated with blocking buffer (0.2% I-block
(Tropix, Bedford, MA), 0.1% Tween 20 in Tris-buffered saline) followed by rabbit-anti ERβ
(1:1000, Alexis Biochemicals, San Diego, CA) overnight at 4°C. The specificity of the ERβ
antibody was demonstrated in our experiments in which a single band (~48 KD) was
detected on western blots. The intensity of the 48 KD band was increased with over-
expression in PC12 cells (Figure 3D), and no bands were detected in U-2 OS cell lysates
(Figure 3B), a cell line that does not express ERβ (Levy et al., 2009). Moreover, the size of
the band detected in PC12 cells was the same as in the PVN (Figure 3C). After washes, the
membranes were incubated with a HRP-conjugated goat anti-rabbit IgG (Jackson
Immunoresearch, West Grove, PA, 1:10,000). The bands were detected with ECL substrate
solution (GE Healthcare Biosciences Corp, Piscataway, NJ) on x-ray film. The membranes
were washed and then incubated with monoclonal mouse actin antibody (MP Biomedicals,
Solon, OH, 1:10,000) and processed for the detection of actin immunoreactivity.
Films from the western blots were analyzed densitometrically using MCID Basic Program
version 7.0 (Interfocus Imaging Ltd., Cambridge, England). The integrated optical density of
protein bands were calculated as previously described (Raap et al., 2000). The density of the
ERβ bands was normalized to the density of the β-actin band in the same sample. The
percent reduction of ERβ expression induced by ERβ-siRNA-Ads during preliminary testing
was calculated by comparing ERβ expression on the side injected with virus to the
contralateral side. To determine the effect of ERβ-siRNA-Ads on EB-induced
desensitization of 5-HT1A receptors, ERβ expression was normalized to actin expression in
the sample, then divided by the mean of the control animals for each immunoblot and
expressed as a percent mean of the control samples.
Radioimmunoassay of plasma oxytocin and ACTH
Plasma oxytocin was determined by a radioimmunoassay as previously described with
minor modifications (Li et al., 1997). Briefly, oxytocin was extracted from 0.5 mL plasma
with 1 mL cold acetone followed by 2.5 mL of petroleum ether (Li et al., 1997). The ether
layer (top layer) was aspirated and the samples were dried in a Centrivap vacuum
concentrator at 4°C. The dried oxytocin residue was resuspended in 1mL of cold assay
buffer (0.05M phosphate buffer pH7.4 containing 0.125% bovine serum albumin and
0.001M EDTA). The plasma extract (100 or 300 µL) was used for the radioimmunoassay as
previously described. The radioactive 125I oxytocin (specific activity: 2200 Ci/mmol) was
obtained from Perkin Elmer (Waltham, MA). Several standard recovery samples containing
0.5 ml pooled plasma and 8 pg or 16 pg oxytocin were included through the extraction and
assay procedure. The plasma oxytocin was calculated based on the recovery and dilution
factors. Plasma ACTH concentrations were determined by radioimmunoassay as previously
described (Li et al., 1993).
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All data are expressed as means ± SEM. Oxytocin and ACTH data were analyzed by a two-
way analysis of variance (ANOVA) for the DPN experiments or three-way ANOVA for the
estrogen siRNA viral injection experiments and a Student-Newman Keuls post hoc test
(Statview version 5.0 software, SAS Institute Inc., Cary, NC). Animals with misplaced
injections or that were injected with the siRNA construct for ERβ but did not have a
decrease in ERβ expression were excluded from the data analysis.
Results
Experiment 1: Effect of selective estrogen receptor beta (ERβ) agonist, DPN, on 5-HT1A
receptor function
DPN has a low affinity for GPR30—To determine the affinity of DPN for GPR30, we
conducted a competitive 3H-E2 binding assay using cell membranes prepared from HEK293
cells transfected with human GPR30. As shown in figure 1, E2 is able to completely inhibit
the 3H-E2 binding to GPR30 with a Ki ~ 10−7M. The competition curve of DPN was shifted
to the right relative to E2. The 3H-E2 binding was not completely blocked even with 10−5M
of DPN. These results suggest that the affinity of DPN to GPR30 is at least 100 fold lower
than E2.
Effect of DPN treatment on 5-HT1A receptor function—Two days of treatment with
the ERβ agonist, DPN, did not alter the baseline levels of plasma oxytocin in comparison to
the vehicle-treated animals (Figure 2A). Activation of 5-HT1A receptors by (+)8-OH-DPAT
increased plasma oxytocin levels as expected, but DPN treatment did not alter this increase
(Figure 2A). The two-way ANOVA for plasma oxytocin indicated a significant effect of
(+)8-OH-DPAT injection (F(1, 35) = 218.7, p<0.0001), but no significant effect of DPN
treatment (F(1, 35) = 0.13, p= 0.72) and no significant interaction between DPN treatment
and (+)8-OH-DPAT injection (F(1,35) = 0.095, p=0.76).
Baseline plasma ACTH levels were not different in animals treated with DPN in comparison
to the vehicle-treated animals (Figure 2B). As expected, 5-HT1A receptor activation by (+)8-
OH-DPAT increased plasma ACTH levels, but DPN treatment had no effect on the (+)8-
OH-DPAT-induced increase in the plasma ACTH (Figure 2B). The two-way ANOVA for
plasma ACTH indicated a significant effect of (+)8-OH-DPAT injection (F(1, 35) = 304.7,
p<0.0001), but no significant effect of DPN treatment (F(1, 35) = 0.45, p= 0.51) and no
significant interaction between DPN treatment and (+)8-OH-DPAT injection (F(1,35) = 0.48,
p=0.5).
Experiment 2: Effect of recombinant adenovirus containing ERβ siRNA on EB-induced
desensitization of 5-HT1A receptors
Selection and evaluation of ERβ-siRNA-Ads—Of the four ERβ siRNAs tested in
PC12 cells, siRNA1 and 2 reduced ERβ mRNA more than 75%, whereas the siRNA3 and 4
only reduced ERβ mRNA about 20% (data not shown). Therefore, we selected the ERβ
siRNA1 and 2 for further analysis. SOS-ERβ-siRNA-HUSs and SOS-ERβ-HUS were
generated and transfected into HEK 293 cells. As shown in Figure 3A, the number and
brightness of GFP-containing cells in SOS-ERβ-siRNA-HUS-transfected cells is
significantly lower than that in SOS-ERβ-HUS-transfected cells. Consistent with these
results, we also found that ERβ in the SOS-ERβ-siRNA-HUS-transfected cells was reduced
relative to the SOS-ERβ-HUS-transfected cells using an immunoblot assay (Fig. 3D). Thus,
the ERβ siRNA1 and 2 were selected for production of ERβ siRNA recombinant adenovirus.
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To test whether high titer ERβ-siRNA-Ads are able to reduce the ERβ expression in vivo,
we unilaterally injected the high titer ERβ-siRNA-Ads into the PVN. As shown in Figure
3E, the ERβ levels in the ERβ-siRNA-Ad injected sides were lower than that in the
contralateral uninjected sides. The percent of inhibition was within the range of 47% to 81%
(n=5). The reduction of ERβ expression was slightly larger seven days than ten days after
viral injection (data not shown).
ERβ in PVN following ERβ-siRNA-Ads injection and EB treatment—Viral
injections were monitored by the presence of RFP in the PVN as shown for one animal in
Fig. 3F. Animals with incorrect injections were not included in subsequent analyses. We
used both the ERβ levels in the PVN and the location of RFP expression as exclusion
criteria for “incorrect injections”of ERβ-siRNA-Ads. Rats that did not express RFP in the
PVN were excluded first (< 10%). We also excluded the rats for which the reduction of ERβ
was less than 20%. The overall rate of successful injection was ~75%. Among rats with
incorrect injections, the hormone responses to 8-OH-DPAT were similar to those Ad-track
viral injected rats. No changes in the basal hormone levels or other behaviors were observed
in the rats with incorrect injections.
Alterations in ERβ after EB treatment and/or ERβ-siRNA-Ads injection were measured
using immunoblot analysis (Figure 4). Two days of EB treatment decreased ERβ protein
levels in the PVN by 33% in animals microinjected with the control adenovirus.
Microinjection with the ERβ-siRNA-Ads resulted in 34% decrease in ERβ protein levels. In
animals treated with both ERβ-siRNA-Ads and EB, ERβ protein levels decreased by 50% in
the PVN. The two-way ANOVA for ERβ protein levels indicated a significant effect of the
viral injection (F(1, 34) = 18.1, p = 0.0002) and significant effect of EB treatment (F(1, 34) =
16.9, p = 0.0002), but no significant interaction between the viral injection and EB treatment
(F(1,34) = 1.81, p=0.19).
Effect of ERβ-siRNA-Ads on EB-induced desensitization of 5-HT1A receptors
—There was no difference in the baseline levels of plasma oxytocin in control virus-injected
or ERβ-siRNA-Ads-injected animals (Figure 5A). (+)8-OH-DPAT increased plasma
oxytocin levels in the control viral-injected and ERβ-siRNA-Ads-injected groups. EB
treatment decreased the oxytocin response to (+)8-OH-DPAT by 28% and 30% in
comparison to the oil-treated animals in the control viral-injected and ERβ-siRNA-Ads-
injected animals, respectively (Figure 5A). The injection of ERβ-siRNA-Ads did not alter
the effects of EB treatment on (+)8-OH-DPAT-stimulated oxytocin release in comparison to
the control virus- injection. The three-way ANOVA for plasma oxytocin indicated a
significant effect of (+)8-OH-DPAT injection (F(1, 40) = 220.85, p<0.0001), EB treatment
(F(1, 40) = 10.386, p=0.0025), and a significant interaction between EB treatment and (+)8-
OH-DPAT injection (F(1,40) = 6.986, p = 0.01). However, there was no significant effect of
viral injection (F(1, 40) = 0.072, p= 0.79) and no significant interaction between the viral
injection and EB treatment (F(1,40) = 0.191, p = 0.66), viral injection and (+)8-OH-DPAT
injection (F(1,40) = 0.007, p = 0.93), or viral injection, EB treatment, and (+)8-OH-DPAT
injection (F(1,40) = 0.045, p = 0.83).
Baseline levels of plasma ACTH were not different in control viral-injected or ERβ-siRNA-
Ads-injected animals. In the control viral-injected animals, (+)8-OH-DPAT increased
plasma ACTH levels. The effect of (+)8-OH-DPAT was decreased 23% by EB treatment
(Figure 5B). In the ERβ-siRNA-Ads injected animals, the ACTH response to (+)8-OH-
DPAT in oil-injected animals was 27% lower than that in the control virus/oil-injected
animals (Figure 5B). In the ERβ-siRNA-Ads-injected animals, EB treatment resulted in a
43% increase in the plasma ACTH response to (+)8-OH-DPAT in comparison to the ERβ-
siRNA-Ads/oil-injected animals (Figure 5B). The three-way ANOVA for plasma ACTH
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indicated a significant effect of EB treatment (F(1, 46) = 4.29, p < 0.05), (+)8-OH-DPAT
injection (F(1, 46) = 390.18, p<0.0001), significant interaction between viral injection and EB
treatment (F(1,46) = 22.41, p<0.0001), and significant interaction between the viral injection,
EB treatment, and (+)8-OH-DPAT injection (F(1,46) = 20.11, p<0.0001). There was no
significant effect of the viral injection (F(1, 46) = 2.1, p = 0.16), no significant interaction
between the viral injection and (+)8-OH-DPAT injection (F(1,46) = 1.741, p = 0.19), or
between the EB treatment and (+)8-OH-DPAT injection (F(1,46) = 3.11, p = 0.08).
Discussion
Previously, we reported that peripheral administration of EB or intra-PVN injections of G-1,
a selective GPR30 agonist, for two days resulted in desensitization of 5-HT1A receptor
signaling in the PVN (D'Souza et al., 2004; Raap et al., 2000; Xu et al., 2009). In the current
study, we found that EB-mediated desensitization of the 5-HT1A receptor signaling in the
PVN is independent of ERβ. However the effects of estradiol on ACTH release are more
complex.
To determine whether ERβ is involved in the EB-induced desensitization of 5-HT1A
receptor signaling in the PVN, we first examined the effects of ERβ agonist, DPN, on
neuroendocrine responses to 5-HT1A receptor activation. Since treatment with GPR30
agonists result in desensitization of 5-HT1A receptor signaling (Xu et al., 2009) and no data
were available concerning the affinity of DPN for GPR30, we determined the affinity of
DPN for GPR30. We found that DPN has a 100 fold lower affinity for the GPR30 receptor
in comparison to EB. Thus, DPN could be used to selectively stimulate ERβ. We found that
DPN administration for two days did not alter the 5-HT1A receptor-stimulated release of
oxytocin and ACTH. The dose of DPN (2 mg/kg) used in the current experiments is
comparable to an effective dose used by other investigators in female rats to activate ERβ as
demonstrated by decreases in anxiety behaviors, regulation of dopamine-2 receptors, and
increases in cell proliferation (Le Saux et al., 2006; Lund et al., 2005; Mazzucco et al.,
2006). Therefore, the present results suggest that activation of ERβ may be not involved in
the desensitization of the 5-HT1A receptor signaling in the PVN. We used the same number
of doses and timepoints for administration of DPN that we used for EB administration in
order to determine if EB was working via ERβ. However, it is possible that other time points
for administration of DPN would result in desensitization of 5-HT1A receptor signaling in
the PVN.
To further evaluate the contribution of ERβ to the EB-mediated desensitization of the 5-
HT1A receptor signaling, an adenovirus containing siRNA sequences against ERβ (ERβ
siRNA-Ads) was directly injected into the PVN. Treatment with the ERβ siRNA-Ads
decreased the protein levels of ERβ in the PVN by 34%. On the other hand, administration
of EB for two days reduced the protein level of ERβ in the PVN by a comparable amount,
33%. This is consistent with the findings from other investigators who found that three to
seven days of treatment with EB decreases ERβ mRNA and protein expression in the PVN
(Patisaul et al., 1999; Suzuki and Handa, 2004). We found that EB administration regulates
ERβ protein levels in the PVN to a similar extent as our ERβ siRNA-Ads injections. The
combined treatment with both EB and ERβ siRNA-Ads resulted in a 50% decrease in the
protein levels of ERβ in the PVN.
As we previously observed, two days of EB treatment desensitized 5-HT1A receptor
signaling in oxytocin cells in the PVN (D'Souza et al., 2004; Raap et al., 2000). It appears
that ERβ does not mediate the EB-induced desensitization of the 5-HT1A receptor signaling
in oxytocin cells in the PVN based on the results from both experiments. First, treatment
with the selective ERβ agonist DPN for two days did not desensitize 5-HT1A receptor
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signaling. Secondly, decreasing the ERβ levels in the PVN did not alter the effects of EB on
5-HT1A receptor agonist-stimulated release of oxytocin. The oxytocin neurons express very
little ERα (Simonian and Herbison, 1997), thus this receptor is unlikely to contribute to the
desensitization of the 5-HT1A receptors. However, studies to directly address the role of
ERα in EB-mediated desensitization of 5-HT1A receptor signaling are needed to
unequivocally resolve the question. Taken together with our previous findings that two days
of treatment with the selective GPR30 agonist G-1 induces desensitization of 5-HT1A
receptors (Xu et al., 2009), we propose that GPR30 mediates the EB-induced desensitization
of the 5-HT1A receptor signaling in oxytocin cells.
EB-induced regulation of 5-HT1A receptor signaling in CRH-containing cells in the PVN,
measured using ACTH as the peripheral marker for central activation of CRH neurons, is
more complex. EB treatment has not been shown to consistently desensitize 5-HT1A
receptor-mediated ACTH release (D'Souza et al., 2004; Raap et al., 2000). In the current
experiment, desensitization of the 5-HT1A receptor signaling in CRH-containing cells was
observed in rats treated with the control virus and EB. Based on our DPN data, it would
appear that ERβ is not directly involved in the desensitization of the 5-HT1A receptor
signaling in CRH cells. However, decreasing ERβ in the PVN differentially altered the
ACTH response to 5-HT1A receptor activation in oil and EB treated rats. Recent reports
suggest that estrogens and their receptors regulate CRH expression and release via complex
mechanisms (Solomon and Herman, 2009). The ACTH response to 5-HT1A receptor
activation in ERβ-siRNA-Ad injected rats may be mediated by different mechanisms in the
absence and presence EB. We speculate that the decrease in ACTH release in the ERβ-
siRNA-Ads/oil treated animals could be due to ERβ-mediated EB-independent regulation.
Some splice variants of ERβ can function as transcription factors in the absence of ligand
resulting in increased expression of several proteins including CRH (Miller et al., 2004) and
CRH binding protein (van de Stolpe et al., 2004). Thus it would follow that decreasing ERβ
expression with the ERβ-siRNA-Ads could decrease the transcription of CRH and reduce
plasma ACTH levels. On the other hand, in the presence of EB, the activation of CRH
neurons is regulated by both ERα and ERβ with opposite effects (Weiser and Handa, 2009).
EB-induced activation of ERα in GABAergic neurons of the peri-PVN region impairs
glucocorticoid-dependent negative feedback regulation of the HPA axis, resulting in an
increase in ACTH release (Weiser and Handa, 2009). In contrast, activation of ERβ in the
PVN slightly suppresses ACTH release (Weiser and Handa, 2009). Thus, the net effect of
EB on HPA axis activity depends on the balance of ERα and ERβ actions. In ERβ-siRNA-
Ad treated rats, the activity of ERβ is decreased, resulting in an unopposed action of ERα in
response to EB treatment that may explain why the ACTH response to 8-OH-DPAT is
potentiated in these rats. Further studies are needed to test these possible underlying
mechanisms.
Several groups have shown that estrogen regulates 5-HT1A receptors in various regions of
the brain, but the specific estrogen receptor subtypes involved have not been directly
addressed as in this current study. We focused on the regulation of 5-HT1A receptors in the
PVN by estrogen because this region is important in the regulation of stress and the control
of mood (Carrasco and Van de Kar, 2003; Legros et al., 1993; Raadsheer et al., 1995). Since
desensitization of pre-synaptic and post-synaptic 5-HT1A receptors may be an underlying
mechanism by which SSRIs slowly mediate their therapeutic effects (Bosker et al., 2001;
Chaput et al., 1986; Czachura and Rasmussen, 2000; Kreiss and Lucki, 1995), it is important
to determine which estrogen receptors are capable of rapid desensitization of 5-HT1A
receptor function. The current study suggests that in the PVN the 5-HT1A receptor
desensitization is independent of ERβ. It was previously demonstrated that 1) 5-HT1A
receptors in the PVN mediate the increased release of oxytocin and ACTH that is induced by
peripheral injections of 8-OH-DPAT (Osei-Owasu et al., 2005) and 2) that the
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desensitization response induced by peripheral estradiol injections can be blocked by intra-
PVN injections of pertussis toxin Xu et al., 2008). Further evidence for a direct effect of EB
on desensitization of 5-HT1A receptors in the PVN comes from our previous study that
demonstrated increased expression RGSz1 in the PVN with EB treatment (Carrasco et al.,
2000, Neuroscience). An increase in RGSz1 can underlie the desensitization response since
RGSz1 terminates Gz signaling and we have demonstrated that Gz is the Galpha protein that
mediates 5-HT1A receptor stimulated release of oxytocin and ACTH (Serres et al., 2000, J
Neuroscience). However, indirect effects of EB on 5-HT1A receptor signaling are possible as
are direct effects of EB on oxytocin. Future studies would have to address whether or not
ERβ regulates 5-HT1A receptors in other regions of the brain and also whether ERα is
involved in 5-HT1A receptor regulation in the PVN and other brain regions. Determining
which estrogen receptors mediate the EB-induced desensitization of 5-HT1A receptor
signaling may allow us in the future to design treatments that activate specific estrogen
receptor subtypes as an adjunct treatment with SSRIs for depression and other mood
disorders.
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Example of competition curves of EB and DPN binding in plasma membranes of HEK293
cells stably transfected with GPR30. The data were expressed as a percentage of maximum
specific [3H]E2 binding.
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Oxytocin and ACTH response to (+)8-OH-DPAT in DPN- or vehicle-treated animals. A.
Plasma oxytocin and B. plasma ACTH levels expressed as the mean ± SEM for 7–10
animals. *Significant difference from saline injected animals, p<0.05 by Student-Newman-
Keuls post hoc test.
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Selection and evaluation of ERβ siRNAs. A. Selection of ERβ siRNA1 and 2 in SOS-HUS
vector. SOS-ERβ-siRNA-HUSs or SOS-ERβ-HUSs were transfected into HEK 293 cells.
The number and brightness of GFP-containing cells were compared between SOS-ERβ-
siRNA-HUSs and SOS-ERβ-HUS transfected cells. Both vectors express GFP-tagged ERβ
so a decrease in GFP intensity in the cells transfected with SOS-ERβ-siRNA-HUSs indicates
a decrease in ERβ expression due to the siRNA. Each construct was transfected into three
wells which are represented in each column. B. Identifying the selectivity of ERβ antibody:
an immunoblot prepared with the ERβ antibody and homogenate from rat PVN (5 µg
protein) and a negative control, lysates from U-2 OS cells (5 µg protein) which do not
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express ERβ. The blot was then reprobed with an actin antibody to demonstrate equal
loading of protein in each lane. C. Immunoblot prepared with the ERβ antibody
demonstrates that a single band at approximately 48 KD was detected in both the
homogenate from rat PVN and PC12 cells lysates. D. Immunoblot for ERβ from PC12 cells
transfected with different constructs. siRNA1, siRNA2 and ERβ represent the cells
transfected with SOS-ERβ-siRNA1-HUS, SOS-ERβ-siRNA2-HUS and SOS-ERβ-HUS,
respectively. The control designation indicates non-transfected cells. E. Example of an
immunoblot for evaluation of the knockdown effect of ERβ with virally expressed siRNA in
vivo. High titer ERβ-siRNA1-Ad and ERβ-siRNA2-Ad were unilaterally injected into the
PVN of rats. ERβ levels in the injected side were compared with the contralateral side. F. An
example of RFP labeling in the PVN to show the position of the viral injection. The images
were captured from a fresh frozen brain section. The left panel was captured under
fluorescent light, while the right panel was captured under bright field and fluorescent light
combined in order to show the location of injection relative to the third ventricle (3V).
Calibration bar indicates 100 microns.
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Effect of ERβ- siRNA-Ads and EB injection on ERβ protein levels in the PVN. A. An
example of an immunoblot of ERβ and β-actin. B. Western blot data analysis of ERβ. Data
are expressed as mean ± SEM for 9–10 animals. *Significant difference from control virus/
oil injected animals, p<0.05 by Student-Newman-Keuls post hoc test.
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Effects of ERβ-siRNA-Ads on EB-induced alteration in the plasma oxytocin (A) and ACTH
(B) response to (+)8-OH-DPAT. Data are presented as mean ± SEM (n=4–10). *:
Significant difference from saline-challenged animals with same pre-treatment., #:
significant difference from control virus/oil/(+)8-OH-DPAT injected animal, &: significant
difference from ERβ-siRNA-Ads/oil/(+)8-OH-DPAT injected animals, @: significant
difference from ERβ-siRNA-Ads/oil/(+)8-OH-DPAT injected, control virus/oil/(+)8-OH-
DPAT injected, and control virus/EB/(+)8-OH-DPAT injected animals, (p<0.05) by
Student-Newman-Keuls post hoc test.
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